The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan
Introduction
Like in most European Union countries and the United States, breast cancer is among the most common cancers in women in Hungary. The improved survival rates may be attributed to increased efficiency of screening programs and better utilization of available treatment modalities. However, choosing the best therapeutic plan requires exact staging information. The course of action in a breast cancer case reported to be early-stage by traditional diagnostic methods – and thus referred to primary surgery – may be completely altered by the presumed or confirmed presence of distant metastases and extensive axillary or extra-axillary lymphatic spreading. 18-FDG PET/CT – incorporating the metabolic data provided by PET and the structural imaging of a CT scan into one modality, thus improving the specificity of the evaluation – can be a valuable tool in the preoperative staging process.1, 2
The aim of our study was to assess the value of the extra diagnostic information provided by 18-FDG PET/CT in routine surgical practice in breast cancer cases considered early-stage and thus candidates for primary surgery by conventional diagnostic modalities. We also examined whether PET/CT data have resulted in changes to clinical disease stage designation or to the originally outlined therapeutic plan.
Section snippets
Patients
Between February 2008 and February 2010, whole-body 18-FDG PET/CT was performed on 115 patients who had breast cancer as confirmed by fine needle aspiration or core biopsy, for whom traditional diagnostic modalities showed no signs of distant metastases or extensive axillary and/or extra-axillary lymphatic spreading (N0–N1), and the size of whose primary tumors was <4 cm. Bilateral mammography, breast and abdominal ultrasound (US), chest X-ray and bone scintigraphy were performed on all the
Results
The clinical staging of breast cancer is based on the TNM classification which requires detailed information on the size of the primary tumor, axillary and extra-axillary lymphatic status, and the presence or absence of any distant metastases.
Between February 2008 and February 2010, all those 115 of author ZG’s patients who fulfilled the above-mentioned criteria were enrolled into the study. Relevant characteristics of the patients are listed in Table 1. No surgery was performed in two
Discussion
The clinical role of PET and PET/CT in the complex diagnosis and staging of breast cancer was evaluated in numerous studies, the first published by Minn and Soini.3 Several authors confirmed that PET/CT facilitates more precise diagnostic assessments than a PET or CT scan alone.1, 2
Conclusion
PET/CT is able to assess primary tumor size and axillary lymphatic status significantly more accurately than traditional diagnostic methods. It can detect distant metastases in 7–8% of those patients who were declared free of metastasis by clinical investigations. As a result, a PET/CT scan modifies the disease stage determined by traditional diagnostic modalities in almost half of the patients and leads to a major change in the treatment plan in every 6th patient. There is no significant
Conflict of interest statement
There is no conflict of interest for any of the authors of the manuscript.
References (30)
- et al.
Evolving role of positron emission tomography in breast cancer imaging
Semin Nucl Med
(2005) - et al.
18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer
EJSO
(2004) - et al.
Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer
Eur J Cancer
(2005) - et al.
Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience
World J Surg
(2009) - et al.
Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis
Eur J Surg Oncol
(2011) - et al.
Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer
Eur J Surg Oncol
(2011) - et al.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Ann Onc
(2009) - et al.
The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer
Clin Positron Imaging
(2000) - et al.
Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications
Ann Oncol
(2005) - et al.
A combined PET/CT scanner for clinical oncology
J Nucl Med
(2000)